In CY 2024, four of these qualifying nonopioid products were separately payable without the 18 percent payment limitationHCPCS Codes C9089 (Bupivacaine implant, 1 mg), J0666 (Inj, bupivacaine liposome), J1096 (Dexametha opth insert 0.1 mg), and J1097 (Phenylep ketorolac opth soln)
The committees recommendations are only one step in a much longer regulatory process
Replace devices according to manufacturer recommendations
Cutler, S.A., Lonergan, S.M., Cornick, N., Johnson, A.K., and Stahl, C.H., Antimicrob
FOCUS found that the drug-device combination had an overall response rate of 36.3%, including seven complete responders and 26 partial responders, with treatment response lasting for a median of 14 months
Key Mechanistic Differences# The mechanistic distinction is significant: Dihexa promotes structural synaptic plasticity through growth factor signaling (building new connections), while PE-22-28 modulates functional neuronal properties through ion channel blockade (changing how existing neurons fire)